CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies

CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies

Abstract Adoptive cell therapy has received a great deal of interest in the treatment of advanced cancers that are resistant to traditional therapy. The tremendous success of chimeric antigen receptor (CAR)-engineered T (CAR-T) cells in the treatment of cancer, especially hematological cancers, has...

Full description

Bibliographic Details
Main Authors: Faroogh Marofi, Marwan Mahmood Saleh, Heshu Sulaiman Rahman, Wanich Suksatan, Moaed E. Al-Gazally, Walid Kamal Abdelbasset, Lakshmi Thangavelu, Alexei Valerievich Yumashev, Ali Hassanzadeh, Mahboubeh Yazdanifar, Roza Motavalli, Yashwant Pathak, Adel Naimi, Behzad Baradaran, Marzieh Nikoo, Farhad Motavalli Khiavi
Format: Article
Language:English
Published: BMC 2021-07-01
Series:Stem Cell Research & Therapy
Subjects:
Natural killer (NK) cells
Chimeric antigen receptor (CAR)
Immunotherapy
Hematological malignancies
Online Access:https://doi.org/10.1186/s13287-021-02462-y

Internet

https://doi.org/10.1186/s13287-021-02462-y

Similar Items